General studies not related to specific treatments.
Submit updates/corrections .
Apr 8 |
et al., Frontiers in Immunology, doi:10.3389/fimmu.2024.1332425 | Effect of high-dose Spirulina supplementation on hospitalized adults with COVID-19: a randomized controlled trial |
| 85% lower mortality (p=0.0002) and 75% higher hospital discharge (p=0.003). RCT 189 hospitalized COVID-19 patients showing lower mortality and faster recovery with high-dose spirulina. Spirulina treatment also resulted in greater reductions in inflammatory markers such as IL-6, TNF-a, IP-10, CRP, ESR, and ferriti.. | ||
Apr 2 |
et al., Critical Care, doi:10.1186/s13054-024-04869-4 | Vitamin D metabolism in critically ill patients with acute kidney injury: a prospective observational study |
| Non-COVID-19 study of 137 critically ill patients showing significantly lower serum calcitriol in patients with moderate-to-severe acute kidney injury (AKI) compared to critically ill patients without AKI, but no significant difference in.. | ||
Mar 28 |
et al., Scientific Reports, doi:10.1038/s41598-024-57561-6 | Brain temperature and free water increases after mild COVID-19 infection |
| Analysis of 10 patients with brain imaging before and after mild COVID-19 suggesting that the primary route for SARS-CoV-2 entry into the central nervous system (CNS) is via the olfactory nerve in the nasal cavity, a pathway known as the.. | ||
Mar 27 |
et al., Frontiers in Immunology, doi:10.3389/fimmu.2024.1335963 | The fatal contribution of serine protease-related genetic variants to COVID-19 outcomes |
| Cross-sectional study of 1,536 COVID-19 patients in Mexico showing increased mortality associated with the TMPRSS2 rs75603675 AA genotype and the SERPINE1 rs2227692 T allele and TT genotype. The SERPINE1 rs2227692 T allele was also associ.. | ||
Mar 20 |
et al., Scientific Reports, doi:10.1038/s41598-024-55378-x | Comparison of mortality and outcomes of four respiratory viruses in the intensive care unit: a multicenter retrospective study |
| Retrospective 807 ICU patients showing higher mortality with COVID-19 and H1N1 influenza compared to RSV and seasonal influenza. | ||
Mar 11 |
et al., eBioMedicine, doi:10.1016/j.ebiom.2024.105042 | Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls |
| 91% fewer moderate/severe cases (p=0.05), 83% fewer symptomatic cases (p<0.0001), and 60% fewer cases (p=0.0001). Open-label non-randomized trial with 80 participants exposed to confirmed SARS-CoV-2 cases, showing lower risk of infection and milder symptoms with mitoquinone mesylate (Mito-MES) prophylaxis. 40 participants took Mito-MES 20mg daily for.. | ||
Mar 10 |
et al., medRxiv, doi:10.1101/2024.03.08.24303818 | SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk |
| Retrospective 12,538 COVID-19 patients, showing associations between specific SARS-CoV-2 lineages and amino acid mutations and increased hospitalization risk, while infection with omicron was associated with lower hospitalization risk com.. | ||
Feb 29 |
et al., New England Journal of Medicine, doi:10.1056/NEJMoa2311330 | Cognition and Memory after Covid-19 in a Large Community Sample |
| Observational study of 112,964 adults in England completing an online cognitive assessment, showing significant cognitive deficits persisting over a year after COVID-19. The largest deficits were seen with hospitalization and unresolved p.. | ||
Feb 28 |
et al., Journal of Clinical Medicine, doi:10.3390/jcm13051397 | Is COVID-19 Infection a Multiorganic Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2 |
| Review of the extrapulmonary manifestations of SARS-CoV-2 infection, which can affect multiple organs beyond the lungs including the cardiovascular, neurological, gastrointestinal, renal, hepatic, and dermatologic systems. Authors suggest.. | ||
Feb 27 |
et al., Virology, doi:10.1128/mbio.00392-24 | Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling |
| In Vitro study showing cyclosporine A (CsA) and the calcineurin-NFAT inhibitor VIVIT inhibit SARS-CoV-2 infection in lung epithelial Calu-3 cells. Authors find SARS-CoV-2 protein Nsp1 hijacks host NFAT signaling by binding calcineurin A, .. | ||
Feb 22 |
et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkae045 | The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis |
| Systematic review and meta-analysis of 44 RCTs of antiviral treatments for early symptomatic COVID-19, including 52,384 participants, assessing the relationship between the SARS-CoV-2 viral clearance rate and the risk of hospitalization o.. | ||
Feb 21 |
et al., Scientific Reports, doi:10.1038/s41598-024-55013-9 | Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer’s, and diabetes |
| In silico study showing potential COVID-19 treatment benefits by repurposing drugs targeting lysophosphatidic acid receptors (LPARs), which are implicated in the tri-directional relationship between Alzheimer's disease, diabetes, and COVI.. | ||
Feb 16 |
et al., Communications Biology, doi:10.1038/s42003-024-05878-3 | SARS-CoV-2 rapidly evolves lineage-specific phenotypic differences when passaged repeatedly in immune-naïve mice |
| Mouse study demonstrating that SARS-CoV-2 can rapidly acquire mutations altering infectivity, disease severity, and drug resistance even without selective pressure. Antigenic drift can undermine variant-specific treatments like monoclonal.. | ||
Feb 13 |
et al., Frontiers in Immunology, doi:10.3389/fimmu.2023.1282859 | Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches |
| In silico study integrating multi-omics data analysis, computational modelling, text mining, and AI to suggest targeted COVID-19 therapies. Authors identified 54 potential targets using omic data analysis of SARS-CoV-2 infected cell lines.. | ||
Jan 31 |
et al., Food and Environmental Virology, doi:10.1007/s12560-023-09581-0 | Screening Commercial Tea for Rapid Inactivation of Infectious SARS-CoV-2 in Saliva |
| In Vitro study showing that certain teas can rapidly inactivate SARS-CoV-2 in saliva. At 10 mg/mL infusion, black tea showed the highest reduction (99.9%) of infectious SARS-CoV-2 within 10 seconds. Green, mint medley, eucalyptus mint, an.. | ||
Jan 31 |
et al., iScience, doi:10.1016/j.isci.2024.109049 | Bioluminescence Imaging Reveals Enhanced SARS-CoV-2 Clearance in Mice with Combinatorial Regimens |
| Mouse study showing that monotherapy with approved antiviral drugs favipiravir, molnupiravir or nirmatrelvir reduced but did not clear SARS-CoV-2 Delta and Omicron variants in K18-hACE2 mice. Combination therapy with molnupiravir and nirm.. | ||
Jan 25 |
et al., Viruses, doi:10.3390/v16020177 | Causes and Consequences of Coronavirus Spike Protein Variability |
| Review of causes and consequences of coronavirus spike protein variability focused on SARS-CoV-2. Authors discuss initial features of the SARS-CoV-2 spike protein and subsequent adaptations to the human host that may have enabled the COVI.. | ||
Jan 23 |
et al., Viruses, doi:10.3390/v16020168 | In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants |
| In vitro study showing additive or synergistic antiviral effects with combinations of COVID-19 therapeutics nirmatrelvir, molnupiravir, remdesivir, and monoclonal antibodies sotrovimab, bebtelovimab, cilgavimab and tixagevimab against anc.. | ||
Sep 21 2023 |
et al., Journal of Clinical Epidemiology, doi:10.1016/j.jclinepi.2023.08.011 | No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study |
| Meta-epidemiological study including 37 meta-analyses with 114 RCTs assessing pharmacological treatments for COVID-19, showing no evidence of an important difference in meta analysis results between preprints and peer-reviewed publications. | ||
Jul 11 2022 |
et al., Biomolecules, doi:10.3390/biom12070971 | Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches |
| Review of the pathological features, neuroinflammatory mechanisms, and potential therapeutic approaches for SARS-CoV-2 in the brain. The review discusses the neuro-invasive potential of SARS-CoV-2 and possible entry routes into the brain,.. | ||
Sep 11 2021 |
et al., Virus Genes, doi:10.1007/s11262-021-01869-2 | Host proviral and antiviral factors for SARS-CoV-2 |
| Review of host proviral and antiviral factors for SARS-CoV-2. Authors summarize current understanding of the interplay between SARS-CoV-2 and host cellular factors during virus entry and replication. They highlight ACE2 as the main recept.. | ||
Jan 21 2020 |
et al., BMJ, doi:10.1136/bmj.l6802 | Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study |
| Meta-analysis of 142 meta-analyses (1,153 trials) finding no evidence that lack of blinding of patients, healthcare providers, or outcome assessors influenced effect estimates in randomized clinical trials on average. | ||
Aug 20 2003 |
et al., JAMA, doi:10.1001/jama.290.7.921 | Association of Funding and Conclusions in Randomized Drug Trials |
| Analysis of randomized drug trials included in Cochrane reviews, showing that trials funded by for-profit organizations were significantly more likely to recommend the experimental drug as treatment of choice (OR 5.3 [2.0-14.4]) compared .. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.